Patents by Inventor Anastasia SHAPIRO
Anastasia SHAPIRO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11981896Abstract: Compositions of matter comprising RNA silencing molecules capable of mediating cleavage of p21 mRNA are disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.Type: GrantFiled: June 28, 2023Date of Patent: May 14, 2024Assignee: 1E Therapeutics Ltd.Inventors: Noam Pilpel, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
-
Patent number: 11939574Abstract: The present invention provides ribosomal RNA origami nanostructures and in particular nanostructures comprising RNA staples, composition comprising such origami nanostructures as well as methods for manufacturing such origami structures.Type: GrantFiled: January 18, 2018Date of Patent: March 26, 2024Assignee: AUGMANITY NANO LTDInventors: Anastasia Shapiro, Ido Bachelet, Yaniv Amir, Erez Lavi, Danielle Karo-Atar
-
Publication number: 20240076671Abstract: A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42, 45-48, 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.Type: ApplicationFiled: September 28, 2023Publication date: March 7, 2024Applicant: RehovotInventors: NOAM PILPEL, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
-
Patent number: 11879140Abstract: A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42, 45-48, 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.Type: GrantFiled: June 28, 2023Date of Patent: January 23, 2024Assignee: 1E THERAPEUTICS LTD.Inventors: Noam Pilpel, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
-
Publication number: 20230416750Abstract: An oligonucleotide is provided. The oligonucleotide comprising a nucleic acid sequence of at least one DNAzyme, the DNAzyme being capable of silencing at least one target gene of a bacteria to thereby render the bacteria susceptible to antibiotic treatment.Type: ApplicationFiled: November 9, 2021Publication date: December 28, 2023Applicant: 1E Therapeutics Ltd.Inventors: Ido Bachelet, Almogit Horowitz, Alexander Rosenberg, Anastasia Shapiro, Ron Oshri, Ilana Kolodkin-Gal, Adva Levy-Zamir, Gat Krieger, Ella GILLIS, Shmulik ITTAH
-
Publication number: 20230365952Abstract: A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42. 45-48. 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.Type: ApplicationFiled: June 28, 2023Publication date: November 16, 2023Applicant: 1E Therapeutics Ltd.Inventors: NOAM PILPEL, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
-
Publication number: 20230357771Abstract: Compositions of matter comprising RNA silencing molecules capable of mediating cleavage of p21 mRNA are disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.Type: ApplicationFiled: June 28, 2023Publication date: November 9, 2023Applicant: 1E Therapeutics Ltd.Inventors: NOAM PILPEL, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
-
Publication number: 20210198674Abstract: The present disclosure describes compositions and methods for rapid selection of both binding and functional oligonucleotides (DNA, RNA, or any natural or synthetic analog of these). In certain embodiments, provided herein are flow cells (e.g., flow cells for an Illumina sequencing instrument or a Polonator sequencing instrument) comprising within its flow chamber a plurality of immobilized aptamer clusters (e.g., from an aptamer library described herein) and, optionally, one or more target cells (e.g., cancer cells, immune cells, etc.) and/or a detectable indicator of cellular function (e.g., a fluorescent indicator of apoptosis, cell proliferation, gene or protein expression, etc.). In certain embodiments, provided herein are methods of using such an aptamer cluster-containing flow cell to identify functional aptamers from an aptamer library (e.g., in a sequencing instrument, such as an Illumina sequencing instrument).Type: ApplicationFiled: March 3, 2021Publication date: July 1, 2021Inventors: Ido Bachelet, Noam Mamet, Itai Rusinek, Gil Harari, Anastasia Shapiro, Yaniv Amir, Erez Lavi, Almogit Abu-Horowitz
-
Publication number: 20210155931Abstract: The present disclosure describes methods and compositions for the treatment of rapidly evolving biological entities (e.g., cancer cells, bacteria, virus, etc.) using therapeutic nucleic acids.Type: ApplicationFiled: May 7, 2018Publication date: May 27, 2021Inventors: Ido Bachelet, Erez Lavi, Sapir Sasson, Liron A. Bassali, Elinor Debby, Anastasia Shapiro, Itai Rusinek, Gil Harai, Danielle Karo-Atar, Noam Mamet, Yaniv Amir, Almogit Abu-Horowitz
-
Publication number: 20200339981Abstract: The present invention provides to a set of anti-pathogenic nucleic acids capable of forming in cellulo one or more nucleic acid origami nanostructure together with one or more pathogenic RNA such as ribosomal RNA, pre-rRNA or mRNA present in the pathogenic cells. The present invention further provides nucleic acid constructs comprising the sequences of the set of anti-pathogenic staple nucleic acids and a vector comprising such a nucleic acid construct. Compositions, including pharmaceutical compositions, comprising the sets, the construct or the vector and use thereof are provided as well.Type: ApplicationFiled: July 16, 2020Publication date: October 29, 2020Inventors: Anastasia SHAPIRO, Ido BACHELET, Almogit ABU-HOROWITZ
-
Publication number: 20200032266Abstract: The present disclosure describes compositions and methods for rapid selection of both binding and functional oligonucleotides (DNA, RNA, or any natural or synthetic analog of these). In certain embodiments, provided herein are flow cells (e.g., flow cells for an Illumina sequencing instrument or a Polonator sequencing instrument) comprising within its flow chamber a plurality of immobilized aptamer clusters (e.g., from an aptamer library described herein) and, optionally, one or more target cells (e.g., cancer cells, immune cells, etc.) and/or a detectable indicator of cellular function (e.g., a fluorescent indicator of apoptosis, cell proliferation, gene or protein expression, etc.). In certain embodiments, provided herein are methods of using such an aptamer cluster-containing flow cell to identify functional aptamers from an aptamer library (e.g., in a sequencing instrument, such as an Illumina sequencing instrument).Type: ApplicationFiled: October 11, 2019Publication date: January 30, 2020Inventors: Ido Bachelet, Noam Mamet, Itai Rusinek, Gil Harari, Anastasia Shapiro, Yaniv Amir, Erez Lavi, Almogit Abu-Horowitz
-
Patent number: 10501743Abstract: The present disclosure describes compositions and methods for rapid selection of both binding and functional oligonucleotides (DNA, RNA, or any natural or synthetic analog of these). In certain embodiments, provided herein are flow cells (e.g., flow cells for an Illumina sequencing instrument or a Polonator sequencing instrument) comprising within its flow chamber a plurality of immobilized aptamer clusters (e.g., from an aptamer library described herein) and, optionally, one or more target cells (e.g., cancer cells, immune cells, etc.) and/or a detectable indicator of cellular function (e.g., a fluorescent indicator of apoptosis, cell proliferation, gene or protein expression, etc.). In certain embodiments, provided herein are methods of using such an aptamer cluster-containing flow cell to identify functional aptamers from an aptamer library (e.g., in a sequencing instrument, such as an Illumina sequencing instrument).Type: GrantFiled: October 19, 2018Date of Patent: December 10, 2019Inventors: Ido Bachelet, Noam Mamet, Itai Rusinek, Gil Harari, Anastasia Shapiro, Yaniv Amir, Erez Lavi, Almogit Abu-Horowitz
-
Publication number: 20190352640Abstract: The present invention provides ribosomal RNA origami nanostructures and in particular nanostructures comprising RNA staples, composition comprising such origami nanostructures as well as methods for manufacturing such origami structures.Type: ApplicationFiled: January 18, 2018Publication date: November 21, 2019Inventors: Anastasia SHAPIRO, Ido BACHELET, Yaniv AMIR, Erez LAVI, Danielle KARO-ATAR
-
Patent number: 10420842Abstract: Nucleic acid origami devices are provided that are non-immunogenic and/or resistant to nucleases, which may be activated by one or more external cues, such as ligands, glucose concentration or electromagnetic fields; or used for attenuation or prevention of internalization of cell-surface receptors or prolongation of shelf-life of active agents. Further provided are methods for treating diabetes and methods for preparing the devices.Type: GrantFiled: April 13, 2014Date of Patent: September 24, 2019Assignee: BAR-ILAN UNIVERSITYInventors: Ido Bachelet, Almogit Abu-Horowitz, Eldad Ben-Ishay, Yaniv Amir, Ariel Munitz, Anastasia Shapiro, Amir Shemer, Zeev Zalevsky
-
Publication number: 20190040391Abstract: The present disclosure describes compositions and methods for rapid selection of both binding and functional oligonucleotides (DNA, RNA, or any natural or synthetic analog of these). In certain embodiments, provided herein are flow cells (e.g., flow cells for an Illumina sequencing instrument or a Polonator sequencing instrument) comprising within its flow chamber a plurality of immobilized aptamer clusters (e.g., from an aptamer library described herein) and, optionally, one or more target cells (e.g., cancer cells, immune cells, etc.) and/or a detectable indicator of cellular function (e.g., a fluorescent indicator of apoptosis, cell proliferation, gene or protein expression, etc.). In certain embodiments, provided herein are methods of using such an aptamer cluster-containing flow cell to identify functional aptamers from an aptamer library (e.g., in a sequencing instrument, such as an Illumina sequencing instrument).Type: ApplicationFiled: October 19, 2018Publication date: February 7, 2019Inventors: Ido Bachelet, Noam Mamet, Itai Rusinek, Gil Harari, Anastasia Shapiro, Yaniv Amir, Erez Lavi, Almogit Abu-Horowitz
-
Publication number: 20160082122Abstract: Nucleic acid origami devices are provided that are non-immunogenic and/or resistant to nucleases, which may be activated by one or more external cues, such as ligands, glucose concentration or electromagnetic fields; or used for attenuation or prevention of internalization of cell-surface receptors or prolongation of shelf-life of active agents. Further provided are methods for treating diabetes and methods for preparing the devices.Type: ApplicationFiled: April 13, 2014Publication date: March 24, 2016Inventors: Ido BACHELET, Almogit ABU-HOROWITZ, Eldad BEN-ISHAY, Yaniv AMIR, Ariel MUNITZ, Anastasia SHAPIRO, Amir SHEMER, Zeev ZALEVSKY